Results of Genmab's HuMax-CD4 Phase II Psoriasis Study COPENHAGEN, Denmark, December 12 /PRNewswire/ -- - Summary: In a Phase IIb psoriasis study, HuMax-CD4 did not achieve statistically significant results. Genmab A/S (CSE: GEN) announced today HuMax-CD4 did not achieve statistically significant results in a 118 patient Phase IIb study to treat psoriasis. Analysis of the data indicated that HuMax-CD4 was safe and well tolerated in the studies to date. There was also a statistically significant dose dependent depletion of CD4+ T-cells. Genmab has no further plans to develop HuMax-CD4 for the treatment of psoriasis. Genmab is continuing its two Phase II studies with HuMax-CD4 to treat cutaneous T- cell lymphoma after encouraging results were presented this fall. About HuMax-CD4 HuMax-CD4 is a high affinity human antibody that targets the CD4 receptor on T-lymphocytes. Genmab is also running two Phase II studies concurrently using HuMax-CD4 to treat cutaneous T-cell lymphoma (CTCL). Interim results using the Physician's Global Assessment showed 55% of the early stage and 38% of the advanced stage CTCL patients achieved at least a partial response (more than 50% improvement in their disease). One early stage patient's CTCL was completely cleared. In addition, 9% of the early stage and 23% of the advanced stage patients achieved a minor response (25- 50% improvement). In other measures of the disease state, pruritus (severe and sometimes debilitating itching) was improved in 82% of early stage patients and 69% of advanced stage patients. Pruritus is most likely the single major parameter for reducing quality of life in CTCL patients. Genmab is adding patients to the Phase II CTCL studies at higher dose levels. The dose level has been increased from the original 280mg per week for 16 weeks in the ongoing studies because CD4+ T-cells were not fully depleted in the initial patients. The objective of using higher doses is to improve responses by further reducing the number of CD4+ T-cells and, thus, the number of cancer cells. At present, 10 early stage patients are being treated with 560mg per week and 7 advanced stage patients are being treated at the 980mg weekly dose level. A review of the safety data has indicated that HuMax-CD4 appears to have been safe and well tolerated in clinical trials to date. During the Phase II CTCL studies no Grade 4 adverse events have occurred. There have been only four Grade 3 adverse events and only one of those, skin hypersensitivity, was judged to be possibly treatment related. In addition to CTCL, approximately half of the non-cutaneous T-cell lymphomas express the CD4 receptor on their cell surface and Genmab has also treated a non-cutaneous T-cell lymphoma patient on a compassionate use basis with a good clinical effect. Considering this and the encouraging data from the CTCL study, Genmab is now making plans to initiate a study in non- cutaneous T-cell lymphoma patients in the second half of 2004, especially since these patients also have a dramatic need for new and less toxic therapies. About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(TM ) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit www.genmab.com. Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; " plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. Web site: http://www.genmab.com DATASOURCE: Genmab A/S CONTACT: Sisse P. Hansen, Investor & Public Relations, Genmab A/S, +45 33 44 77 76, or mobile: +45 25 27 47 27, or email: sha@genmab.com

Copyright